Organisation paid for research Program year 2025 Source: CMS Open Payments

Vitreoretinal Surgery PA

Neither a doctor nor a teaching hospital

Research payments

$5,190,730

546 payments

Through program year 2025, Vitreoretinal Surgery PA is reported as receiving $5,190,730 in research payments, across 546 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$80,686	67
2024	Research	$496,065	211
2023	Research	$198,359	68
2022	Research	$203,163	8
2021	Research	$1,673,086	80
2020	Research	$1,607,425	71
2019	Research	$931,946	41

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $3,907,456 210 payments
Bayer HealthCare Pharmaceuticals Inc. $925,376 333 payments
Novartis Pharmaceuticals Corporation $357,898 3 payments

Studies the money was for Research payments · program years 2019–2025

Port Delivery System for Ranibizumab $944,650 37 payments
Va2 Phiii $888,639 29 payments
Va2 Phiii Yosemite $619,329 30 payments
BAY 865321, Aflibercept 8mg in RVO $405,439 171 payments
Study of the Port Delivery System With Ranibizumab in Patients With Diabetic MacUlar Edema $390,859 24 payments
A Randomized Double-Masked, Phase III Study Assessing Brolucizumab Intravitreal Injections Versus Aflibercept in Patients With Visual Impairment Due to MacUlar Edema (Me) Secondary to Central Retinal Vein Occlusion (Crvo) $357,898 3 payments
Port Delivery System of Ranizibumab Extension Study $304,869 22 payments
Port Delivery System of Ranibizumab Extension Study $216,494 10 payments
BAY865321, HD 8mg, AMD - Ph 3 $174,181 9 payments
Phase 2 of Ro7171009 in Ga $168,829 21 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.